Stock data
Ligand Pharmaceuticals Incorporated (LGND)
Ligand Pharmaceuticals Incorporated (LGND) reported revenue of US$268.09M and net income of US$124.45M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$268.09M | — | US$41.00M | US$124.45M | — |
| 2024 | US$167.13M | — | -US$22.61M | -US$4.03M | — |
| 2023 | US$131.31M | — | US$11.94M | US$52.15M | — |
| 2022 | US$196.25M | — | US$3.04M | -US$33.36M | — |
| 2021 | US$241.54M | — | US$103.85M | US$57.14M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$63.69M | US$48.51M | — |
| 2026-03-31 | US$51.72M | -US$13.35M | — |
| 2025-12-31 | US$59.67M | US$44.78M | — |
| 2025-09-30 | US$115.46M | US$117.27M | — |
| 2025-06-30 | US$47.63M | US$4.85M | — |
| 2025-03-31 | US$45.33M | -US$42.45M | — |
| 2024-12-31 | US$42.81M | -US$31.09M | — |
| 2024-09-30 | US$51.81M | -US$7.17M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.